<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04075162</url>
  </required_header>
  <id_info>
    <org_study_id>20190995</org_study_id>
    <nct_id>NCT04075162</nct_id>
  </id_info>
  <brief_title>Community Benefit of No-charge Calcium Score Screening Program</brief_title>
  <acronym>CLARIFY</acronym>
  <official_title>Community Benefit of No-charge Calcium Score Screening Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current approaches in primary prevention for cardiovascular disease are based on&#xD;
      probabilistic approaches to estimate risk, using many of the widely available cardiovascular&#xD;
      risks scores, with over 100 such scoring systems currently available throughout the world.&#xD;
      The rationale for this practice is to select those individuals at greatest risk for more&#xD;
      intense targets, reduce risk of treatment to those at minimal risk, and to maximize the&#xD;
      cost-effectiveness of treatment. A recent Cochrane Systematic Review assessed the practice of&#xD;
      using risk scores to select individuals for the primary prevention of cardiovascular disease.&#xD;
      3 The principal finding of the systematic review was that there was little or no effect of&#xD;
      providing clinicians with cardiovascular risk scores when compared to standard of care (5.4%&#xD;
      versus 5.3%; relative risk 1.01, 95% confidence intervals 0.95 to 1.08). The authors&#xD;
      concluded that there is major uncertainty whether current strategies for providing risk&#xD;
      scores and called for further research to address this concern. Extent of coronary artery&#xD;
      calcium (CAC) is a strong risk marker for coronary events, with evidence mainly derived from&#xD;
      observational studies and from prospective non-randomized studies. CAC, although endorsed for&#xD;
      intermediate risk patients, is not widely adopted due to barriers in reimbursement. The cost&#xD;
      of the test ranges between 100 and 300 USD in the United States, which may have limited the&#xD;
      wide adoption of the test. Whether reducing the cost burden for CAC increases utilization for&#xD;
      routine screening and its influence on physician practices and downstream testing is largely&#xD;
      unknown. University Hospitals started offering low charge CAC (99$) since 2014. In 2017,&#xD;
      University Hospitals started offering CAC for no charge for patients to improve access to&#xD;
      this test, which has not traditionally been covered by insurance companies. The impact of&#xD;
      no-charge CAC has never been studied.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Anticipated">December 2032</completion_date>
  <primary_completion_date type="Anticipated">December 2030</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Statin Prescription</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-invasive coronary ischemia testing</measure>
    <time_frame>1 year</time_frame>
    <description>Stress echocardiograms, myocardial perfusion imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive coronary ischemia testing</measure>
    <time_frame>1 year</time_frame>
    <description>Invasive coronary angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary revascularization procedures</measure>
    <time_frame>1 year</time_frame>
    <description>Percutaneous coronary interventions, coronary artery bypass grafting</description>
  </secondary_outcome>
  <other_outcome>
    <measure>LDL cholesterol</measure>
    <time_frame>1 year</time_frame>
    <description>Change in LDL cholesterol levels from baseline to 1 year</description>
  </other_outcome>
  <other_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>1 year</time_frame>
    <description>Change in LDL cholesterol levels from baseline to 1 year</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood pressure</measure>
    <time_frame>1 year</time_frame>
    <description>Change in blood pressure from baseline to 1 year</description>
  </other_outcome>
  <other_outcome>
    <measure>Body mass index</measure>
    <time_frame>1 year</time_frame>
    <description>Change in BMI from baseline to 1 year</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Triglycerides</measure>
    <time_frame>1 year</time_frame>
    <description>Change in BMI from baseline to 1 year</description>
  </other_outcome>
  <other_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of myocardial infarction</description>
  </other_outcome>
  <other_outcome>
    <measure>Stroke</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of myocardial infarction</description>
  </other_outcome>
  <other_outcome>
    <measure>Death</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of death</description>
  </other_outcome>
  <other_outcome>
    <measure>Lung cancer</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of lung cancer</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">77000</enrollment>
  <condition>Cardiovascular Risk Factor</condition>
  <arm_group>
    <arm_group_label>Low charge CAC</arm_group_label>
    <description>Patients receiving CAC for Cardiovascular disease risk screening at low charge (99 USD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No charge CAC</arm_group_label>
    <description>Patients receiving CAC for Cardiovascular disease risk screening at no charge</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who received a no-cost Coronary Artery Calcium (CAC) CT scan at University&#xD;
        Hospitals (Cleveland, Oh) starting in January 1, 2014.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Received Coronary Artery Calcium (CAC) CT scan at University Hospitals starting in&#xD;
             January 1, 2014.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Sadeer Al-Kindi, M.D.</last_name>
    <phone>2168441000</phone>
    <email>sadeer.alkindi@uhhospitals.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jared C Durieux, Ph.D.(c)</last_name>
    <phone>2168441000</phone>
    <email>jared.durieux@uhhospitals.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Research Specialist</last_name>
      <phone>216-844-5125</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 21, 2019</study_first_submitted>
  <study_first_submitted_qc>August 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2019</study_first_posted>
  <last_update_submitted>August 29, 2019</last_update_submitted>
  <last_update_submitted_qc>August 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals Cleveland Medical Center</investigator_affiliation>
    <investigator_full_name>Sanjay Rajagopalan</investigator_full_name>
    <investigator_title>Division Chief of Cardiovascular Medicine</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

